Psoriasis and NAFLD: Inflammatory Biomarkers as Mediators

Introduction

This study investigates the relationship between psoriasis, a chronic inflammatory skin condition, and nonalcoholic fatty liver disease (NAFLD), a common liver disorder. Given the known association between these two conditions, the research aimed to determine if inflammatory biomarkers play a mediating role in this complex interconnection.

The Study in Detail

The study, titled "The association between psoriasis and nonalcoholic fatty liver disease: Mediation analysis involving inflammatory biomarkers among U.S. adults," was published in PLoS One by Wang et al. The authors utilized data from the National Health and Nutrition Examination Survey (NHANES), specifically from the 2003-2006 and 2009-2014 cycles, focusing on adults aged 20-60 years. Logistic regression was employed to analyze the association between psoriasis and NAFLD across three different models, including subgroup and interaction analyses. A key aspect of the methodology was the mediation analysis, which assessed whether the systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) – both inflammatory markers – mediate the relationship between psoriasis and NAFLD.

A total of 9,439 participants were included in the study. The weighted prevalence rate of NAFLD among these participants was 41.96%, with 3,961 individuals diagnosed with the condition. Participants with psoriasis exhibited a higher prevalence of NAFLD, reaching 50.99%, compared to those without psoriasis. The findings consistently showed a positive association between psoriasis and the risk of NAFLD across all three models, and a significant dose-response relationship was observed (p < 0.05). Crucially, the mediation analysis revealed that, in the adjusted models, Ln-SII and Ln-NLR statistically mediated the association between psoriasis and NAFLD, accounting for 8.52% and 3.58% of the effect, respectively (p < 0.05).

Assessment

The study provides robust evidence for a positive association between psoriasis and NAFLD, further supported by a dose-response relationship. Its strength lies in the use of a large, representative dataset from NHANES, which enhances the generalizability of the findings to the U.S. adult population. The application of mediation analysis is particularly valuable, as it moves beyond simply identifying an association to exploring potential underlying mechanisms. The identification of SII and NLR as mediators suggests that systemic inflammation plays a significant role in connecting these two conditions. However, the study is observational, meaning it cannot establish causality. While it identifies mediation, it does not fully elucidate the intricate biological pathways through which these inflammatory markers exert their influence. The percentage of mediation, while statistically significant, indicates that other factors are also involved in the complex relationship between psoriasis and NAFLD.

Practical Relevance

The findings of this study have important implications for both clinical practice and public health. For individuals with psoriasis, the increased risk of NAFLD highlights the importance of routine screening for liver health, especially given that NAFLD can progress to more severe liver diseases. Conversely, patients diagnosed with NAFLD, particularly those with signs of systemic inflammation, might benefit from evaluation for psoriasis or a deeper understanding of their inflammatory profile. From a nutritional and lifestyle perspective, managing systemic inflammation through dietary interventions (e.g., anti-inflammatory diets rich in omega-3 fatty acids, fruits, and vegetables) and lifestyle modifications (e.g., regular exercise, weight management) could potentially mitigate the risk or progression of NAFLD in individuals with psoriasis. This study underscores the interconnectedness of chronic inflammatory conditions and metabolic health, suggesting a holistic approach to patient care.

Conclusion

This research confirms a significant positive association between psoriasis and nonalcoholic fatty liver disease among U.S. adults. Importantly, it identifies the systemic immune-inflammation index (SII) and neutrophil-to-lymphocyte ratio (NLR) as key inflammatory mediators in this relationship. These findings emphasize the role of systemic inflammation in linking these two conditions and suggest potential avenues for integrated management and preventive strategies.